Stratégie diagnostique des sarcomes des tissus mous de l’enfant et adolescent

Charlotte Collignon (1) , Hervé J. Brisse (1) , Lauriane Lemelle (1) , Liesbeth Cardoen (1) , Arnaud Gauthier (1) , Gaëlle Pierron (1) , Aphaia Roussel (2) , Benoit Dumont (1) , Aurélia Alimi (1) , Camille Cordero (1) , Lucie Rouffiange (1) , Daniel Orbach (1)

1 Institut Curie [Paris]
2 Hôpital Robert Debré

Soft tissue sarcomas in children are rare tumor, representing around 6 to 7% of children cancer. They spread mostly sporadically (90%) and therefore are rarely associated to an underlying constitutional genetic disease (10%). About half of those sarcomas are rhabdomyosarcomas and the others are a very heterogenous histologic group with various bio-pathologies and prognosis. Clinical presentation is mainly a soft tissue lump often difficult to distinguish from more frequent benign causes (malformative, infectious, benign, or pseudotumor). Inappropriate initial diagnosis work-up has a strong impact on soft tissue sarcomas' prognosis. Adapted complementary investigations (first ultrasound and MRI) are important to compile arguments for a malign origin and to indicate a biopsy. However, predictive value of imaging exams still remains imperfect, and histological analysis by percutaneous image-guided biopsy and sometimes by surgical biopsy is often necessary. Authors realize an update on optimal diagnostic pathway including molecular tests in presence of a soft tissue mass in a child.

Mots clés: Adolescents; Diagnostic; Diagnostic guidelines; Pediatric cancer; Pédiatrie; Recommandations de prise en charge; Sarcomes des parties molles; Soft part sarcomas

Domaines: Sciences du Vivant [q-bio]

Charlotte Collignon, Hervé J. Brisse, Lauriane Lemelle, Liesbeth Cardoen, Arnaud Gauthier, et al.. Stratégie diagnostique des sarcomes des tissus mous de l’enfant et adolescent. Bulletin du Cancer, 2020, 107, pp.963 - 971. ⟨10.1016/j.bulcan.2020.06.008⟩. ⟨hal-03494073⟩